TD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the 8 Best Large Cap Stocks to Invest In Right Now. On April 13, TD Cowen reduced its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) from $683 to $625 and kept its Buy rating on the stock.

The research firm raised its Q1 EPS estimate from $5.05 to $5.21 to match the company’s guidance. Thermo Fisher Scientific Inc. (NYSE:TMO) expects 1% organic growth for the first quarter. This guidance includes a 1.8% negative impact due to one less day and a planned customer shutdown.

TD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating

The firm also noted that the company’s management expressed optimism at TD Cowen’s March conference regarding demand trends for Q1 and 2026. TD Cowen pointed out that operating margins in Q1 are expected to fall compared to the same period last year. The research firm added that Q1 will represent the low point for EPS growth.

TD Cowen sees pharma strength and potential preclinical improvement as key factors that will support organic growth acceleration in the second half of the year.

Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading life science and clinical research company that supplies analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical, and biotechnology services.

While we acknowledge the risk and potential of TMO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Performing AI Stocks to Buy and 10 Unrivaled Stocks of the Next 5 Years.

Disclosure: None.  Follow Insider Monkey on Google News.